FDA Approves Breakthrough Drug Rasonque for Metastatic Pancreatic Cancer
In a significant advancement for cancer treatment, the Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib) for the treatment of metastatic pancreatic adenocarcinoma, the most prevalent form of pancreatic cancer. This new medication is designed for patients whose cancer has spread beyond the pancreas and who have previously undergone systemic therapy, such as chemotherapy….
